A Critical Review of the Impact of Sarcoma on Psychosocial Wellbeing

Table 9

QOL measured by the QLQ-C30¹.

First author	Comparator^2	Quality of life^3	Domains^3
Hillmann et al. [56]	Rotationplasty vs. LSS	+	Role
Veenstra et al. [101]	Reference values^4	−^5	PF, RP
Rodl et al. [85]	Reference values	=
Zahlten-Hinguranage et al. [107]	AMP vs. LSS	=
Hoffmann et al. [59]	Hip disarticulation vs. AMP vs. LSS; Reference values	=^6
Paredes et al. [74]	Time: diagnosis to treatment; Reference value	+^5; −; −	GH; PF; PF, RP, GH, SF
Barrera et al. [31]	AMP vs. LSS; Reference values	=; ^7
Reichardt et al. [82]	Metastatic STS vs. metastatic BT; Reference values	ns; ns
Custers et al. [37]	High vs. low fear of recurrence	−
Shchelkova and Usmanova [91]	GCT vs. OS; GCT vs. CS	−^5; −^5	PF, MH, GH, SF; PF, SF
Tang et al. [97]	Distress vs. no distress	−
Poort et al. [79]	Severe fatigue vs. none	−
Podleska et al. [78]	Other cancer patients; Reference values	+; =
Wong et al. [105]	Time: before treatment to 5 years after treatment	ns

AMP: amputation; BT: bone tumour; GCT: giant cell tumour; GH: global health; LSS: limb-sparing surgery; MH: mental health; ns: significance not specified; OS: osteosarcoma; PF: physical function; RP: role-physical; SF: social function; STS: soft tissue sarcoma. ¹Minus (−): poorer in comparison; plus (+): better; equals (=): no difference. ²Direction of significance, i.e., better or worse, based on the first comparator, or the last time point if a longitudinal comparison. ³Result based on overall or summary scores; if these were not provided, result at domain score level was provided (QLQ-C30 functional scale only). ⁴Reference values either supplied with the measure or collected from noncancer controls as part of the study. ⁵Total and/or summary scores can be calculated with the measure used, but this was not reported. ⁶Text is unclear, and data presented in an appendix are no longer available. ⁷Three quality of life measures used, all giving different results.